(SFZN) Siegfried Holding - Ratings and Ratios

Siegfried Holding AG, a Swiss-based company founded in 1873, specializes as a contract development and manufacturing organization (CDMO) for active pharmaceutical ingredients (APIs) and finished dosage forms. The company excels in custom synthesis, offering exclusive APIs tailored to client needs. Its diverse portfolio includes non-exclusive APIs and pharma-grade substances, focusing on anesthetics, pain and addiction management, CNS disorders, respiratory diseases, and caffeine for health and nutrition. Siegfrieds drug products encompass steriles (fill and finish in vials, ampoules, cartridges, pre-filled syringes), ophthalmic products (sterile ointments, gels, suspensions, solutions), inhalation devices (capsules for medical inhalers), oral solids (tablets, capsules), and viral vectors (AAV, lentiviruses) for gene therapy. The companys technological expertise spans chemistry, analytics, formulation, bridging technologies, containment, and cell/gene therapies.

3-Month Forecast: Based on technical and fundamental analysis, Siegfried Holding AG (SFZN) is expected to show moderate growth. With a last price of 930.00 CHF and SMA20 at 878.65, the stock is trading above its 20-day moving average, indicating bullish momentum. The SMA50 at 921.24 and SMA200 at 1031.01 suggest potential resistance at higher levels. ATR of 33.30 indicates moderate volatility. Fundamentally, a P/E of 24.10 and forward P/E of 22.12 suggest improving earnings expectations. A P/B of 3.97 and P/S of 3.01 reflect a premium valuation. With an ROE of 18.79%, the company demonstrates strong profitability. Over the next quarter, SFZN is likely to maintain its upward trajectory, supported by solid earnings growth, though high valuations may pose risks. The stock is expected to trade within a range of 900-980 CHF, with potential upside if it breaks above the SMA200 level.